nach oben

Cancer and Metastasis Reviews

Erschienen in:

14.09.2023 | REVIEW

The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

verfasst von: Priya Mondal, Syed Musthapa Meeran

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Resistance to therapeutic agents is one of the major challenges in cancer therapy. Generally, the focus is given to the genetic driver, especially the genetic mutation behind the therapeutic resistance. However, non-mutational mechanisms, such as epigenetic modifications, and TME alteration, which is mainly driven by cancer cell plasticity, are also involved in therapeutic resistance. The concept of plasticity mainly relies on the conversion of non-cancer stem cells (CSCs) to CSCs or epithelial-to-mesenchymal transition via different mechanisms and various signaling pathways. Cancer plasticity plays a crucial role in therapeutic resistance as cancer cells are able to escape from therapeutics by shifting the phenotype and thereby enhancing tumor progression. New evidence suggests that gut microbiota can change cancer cell characteristics by impacting the mechanisms involved in cancer plasticity. Interestingly, gut microbiota can also influence the therapeutic efficacy of anticancer drugs by modulating the mechanisms involved in cancer cell plasticity. The gut microbiota has been shown to reduce the toxicity of certain clinical drugs. Here, we have documented the critical role of the gut microbiota on the therapeutic efficacy of existing anticancer drugs by altering the cancer plasticity. Hence, the extended knowledge of the emerging role of gut microbiota in cancer cell plasticity can help to develop gut microbiota-based novel therapeutics to overcome the resistance or reduce the toxicity of existing drugs. Furthermore, to improve the effectiveness of therapy, it is necessary to conduct more clinical and preclinical research to fully comprehend the mechanisms of gut microbiota.

Mondal, P., Natesh, J., Salam, A. A. A., & Meeran, S. M. (2022). Mahanimbine isolated from Murraya koenigii inhibits P-glycoprotein involved in lung cancer chemoresistance. Bioorganic Chemistry, 129, 106170. https://doi.org/10.1016/j.bioorg.2022.106170CrossRefPubMed

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: A brief review. Advanced Pharmaceutical Bulletin., 55, 888. https://doi.org/10.15171/apb.2017.041CrossRef

Mondal, P., Natesh, J., Penta, D., & Meeran, S. M. (2020). Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2020.12.006CrossRefPubMed

Mondal, P., Kaur, B., Natesh, J., & Meeran, S. M. (2021). The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications. Seminars in Cell and Developmental Biology. https://doi.org/10.1016/j.semcdb.2021.04.001CrossRefPubMed

Mondal, P., Natesh, J., Kamal, M. A., & Meeran, S. M. (2020). Non-coding RNAs in lung cancer chemoresistance. Current Drug Metabolism, 20(13), 1023–1032. https://doi.org/10.2174/1389200221666200106105201CrossRef

Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021). Battling chemoresistance in cancer: Root causes and strategies to uproot them. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22179451CrossRefPubMedPubMedCentral

Shenoy, S. (2020). Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment. Surgical Oncology. https://doi.org/10.1016/j.suronc.2020.04.017CrossRefPubMed

Vergara, D., Simeone, P., Damato, M., Maffia, M., Lanuti, P., & Trerotola, M. (2019). The cancer microbiota: EMT and inflammation as shared molecular mechanisms associated with plasticity and progression. Journal of Oncology. https://doi.org/10.1155/2019/1253727CrossRefPubMedPubMedCentral

Sevcikova, A., Izoldova, N., Stevurkova, V., Kasperova, B., Chovanec, M., Ciernikova, S., & Mego, M. (2022). The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23010488CrossRefPubMedPubMedCentral

10.

Mondal, P., & Meeran, S. M. (2021). microRNAs in cancer chemoresistance: The sword and the shield. Non-coding RNA Research, 6(4), 200–210. https://doi.org/10.1016/j.ncrna.2021.12.001CrossRefPubMedPubMedCentral

11.

Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-019-0044-1CrossRefPubMed

12.

Fanelli, G. N., Naccarato, A. G., & Scatena, C. (2020). Recent advances in cancer plasticity: Cellular mechanisms, surveillance strategies, and therapeutic optimization. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.00569CrossRefPubMedPubMedCentral

13.

Schepers, A. G., Snippert, H. J., Stange, D. E., Van Den Born, M., Van Es, J. H., Van De Wetering, M., & Clevers, H. (2012). Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science, 337(6095), 730–735. https://doi.org/10.1126/science.1224676CrossRefPubMed

14.

Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012). Defining the mode of tumour growth by clonal analysis. Nature, 488(7412), 527–530. https://doi.org/10.1038/nature11344CrossRefPubMedPubMedCentral

15.

Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488(7412), 522–526. https://doi.org/10.1038/nature11287CrossRefPubMedPubMedCentral

16.

De Sousa E Melo, F., Kurtova, A. V., Harnoss, J. M., Kljavin, N., Hoeck, J. D., Hung, J., … De Sauvage, F. J. (2017). A distinct role for Lgr5 + stem cells in primary and metastatic colon cancer. Nature, 543(7647). https://doi.org/10.1038/nature21713

17.

Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., … Sato, T. (2017). Visualization and targeting of LGR5 + human colon cancer stem cells. Nature, 545(7653). https://doi.org/10.1038/nature22081

18.

Pattabiraman, D. R., & Weinberg, R. A. (2014). Tackling the cancer stem cells-What challenges do they pose? Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4253CrossRefPubMedPubMedCentral

19.

Santoro, A., Vlachou, T., Carminati, M., Pelicci, P. G., & Mapelli, M. (2016). Molecular mechanisms of asymmetric divisions in mammary stem cells. EMBO reports, 17(12), 1700–1720. https://doi.org/10.15252/embr.201643021CrossRefPubMedPubMedCentral

20.

Najafi, M., Mortezaee, K., & Ahadi, R. (2019). Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance. Life Sciences. https://doi.org/10.1016/j.lfs.2019.05.076CrossRefPubMed

21.

Venkei, Z. G., & Yamashita, Y. M. (2018). Emerging mechanisms of asymmetric stem cell division. Journal of Cell Biology. https://doi.org/10.1083/jcb.201807037CrossRefPubMedPubMedCentral

22.

Jin, X., Kim, L. J. Y., Wu, Q., Wallace, L. C., Prager, B. C., Sanvoranart, T., … Rich, J. N. (2017). Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nature Medicine, 23(11). https://doi.org/10.1038/nm.4415

23.

Baumann, M., Krause, M., & Hill, R. (2008). Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer. https://doi.org/10.1038/nrc2419CrossRefPubMed

24.

Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., … Han, C.-H. (2023). Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies. Signal Transduction and Targeted Therapy 2023 8:1, 8(1).

25.

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017). Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Research, 77(15), 3982–3989. https://doi.org/10.1158/0008-5472.CAN-16-3292CrossRefPubMedPubMedCentral

26.

Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., … Song, E. (2014). A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell, 25(5). https://doi.org/10.1016/j.ccr.2014.03.021

27.

Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., … Tüting, T. (2012). Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature, 490(7420). https://doi.org/10.1038/nature11538

28.

Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6(5), 392–401. https://doi.org/10.1038/nrc1877CrossRefPubMed

29.

Li, H. J., Reinhardt, F., Herschman, H. R., & Weinberg, R. A. (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 Signaling. Cancer Discovery, 2(9), 840–855. https://doi.org/10.1158/2159-8290.CD-12-0101CrossRefPubMed

30.

Baram, T., Rubinstein-Achiasaf, L., Ben-Yaakov, H., & Ben-Baruch, A. (2021). Inflammation-driven breast tumor cell plasticity: Stemness/EMT, therapy resistance and dormancy. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.614468CrossRefPubMedPubMedCentral

31.

Fousek, K., Horn, L. A., & Palena, C. (2021). Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2020.107692CrossRefPubMed

32.

Mondal, P., & Meeran, S. M. (2020). Long non-coding RNAs in breast cancer metastasis. Non-coding RNA Research, 5(4), 208–218. https://doi.org/10.1016/j.ncrna.2020.11.004CrossRefPubMedPubMedCentral

33.

Boyer, B., & Thiery, J. P. (1993). Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS. https://doi.org/10.1111/j.1699-0463.1993.tb00109.xCrossRefPubMed

34.

Brabletz, T. (2012). To differentiate or not-routes towards metastasis. Nature Reviews Cancer. https://doi.org/10.1038/nrc3265CrossRefPubMed

35.

Merrell, A. J., & Stanger, B. Z. (2016). Adult cell plasticity in vivo: De-differentiation and transdifferentiation are back in style. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/nrm.2016.24CrossRefPubMedPubMedCentral

36.

Rubin, M. A., Bristow, R. G., Thienger, P. D., Dive, C., & Imielinski, M. (2020). Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers. Molecular Cell. https://doi.org/10.1016/j.molcel.2020.10.033CrossRefPubMedPubMedCentral

37.

Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., … Herlyn, M. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research, 65(20). https://doi.org/10.1158/0008-5472.CAN-05-1343

38.

Battula, V. L., Evans, K. W., Hollier, B. G., Shi, Y., Marini, F. C., Ayyanan, A., … Mani, S. A. (2010). Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells, 28(8). https://doi.org/10.1002/stem.467

39.

Sinha, S., Biswas, M., Chatterjee, S. S., Kumar, S., & Sengupta, A. (2020). Pbrm1 steers mesenchymal stromal cell osteolineage differentiation by integrating PBAF-dependent chromatin remodeling and BMP/TGF-β signaling. Cell Reports, 31(4), 107570. https://doi.org/10.1016/j.celrep.2020.107570CrossRefPubMed

40.

Gao, W., Lin, M., Liang, A., Zhang, L., Chen, C., Liang, G., … Su, P. (2014). Melatonin enhances chondrogenic differentiation of human mesenchymal stem cells. Journal of Pineal Research, 56(1). https://doi.org/10.1111/jpi.12098

41.

Liu, Y., Berendsen, A. D., Jia, S., Lotinun, S., Baron, R., Ferrara, N., & Olsen, B. R. (2012). Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. Journal of Clinical Investigation, 122(9), 3101–3113. https://doi.org/10.1172/JCI61209CrossRefPubMedPubMedCentral

42.

Hinz, S., & LaBarge, M. A. (2019). Hijacking EMT: Better fat than dead. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.12.007CrossRefPubMed

43.

Ishay-Ronen, D., Diepenbruck, M., Kalathur, R. K. R., Sugiyama, N., Tiede, S., Ivanek, R., … Christofori, G. (2019). Gain fat—Lose metastasis: Converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell, 35(1). https://doi.org/10.1016/j.ccell.2018.12.002

44.

Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., … Lowe, S. W. (2014). P53-dependent nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell, 158(3). https://doi.org/10.1016/j.cell.2014.05.051

45.

Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003). Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell, 4(3), 181–189. https://doi.org/10.1016/S1535-6108(03)00220-4CrossRefPubMed

46.

Ku, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., … Goodrich, D. W. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 355(6320). https://doi.org/10.1126/science.aah4199

47.

Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., … Abate-Shen, C. (2017). Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discovery, 7(7). https://doi.org/10.1158/2159-8290.CD-16-1174

48.

Ferone, G., Song, J. Y., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J. P., … Berns, A. (2016). SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell, 30(4). https://doi.org/10.1016/j.ccell.2016.09.001

49.

Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00313-5CrossRefPubMedPubMedCentral

50.

Tan, T., Shi, P., Abbas, M. N., Wang, Y., Xu, J., Chen, Y., & Cui, H. (2022). Epigenetic modification regulates tumor progression and metastasis through EMT (review). International Journal of Oncology. https://doi.org/10.3892/ijo.2022.5360CrossRefPubMedPubMedCentral

51.

Allis, C. D., & Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. Nature Reviews Genetics. https://doi.org/10.1038/nrg.2016.59CrossRefPubMed

52.

da Silva-Diz, V., Lorenzo-Sanz, L., Bernat-Peguera, A., Lopez-Cerda, M., & Muñoz, P. (2018). Cancer cell plasticity: Impact on tumor progression and therapy response. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2018.08.009CrossRefPubMed

53.

Murai, F., Koinuma, D., Shinozaki-Ushiku, A., Fukayama, M., Miyaozono, K., & Ehata, S. (2015). EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discovery, 1. https://doi.org/10.1038/celldisc.2015.26

54.

Svensson, C., Ceder, J., Iglesias-Gato, D., Chuan, Y. C., Pang, S. T., Bjartell, A., … Flores-Morales, A. (2014). REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Research, 42(2). https://doi.org/10.1093/nar/gkt921

55.

Lim, J. S., Ibaseta, A., Fischer, M. M., Cancilla, B., O’Young, G., Cristea, S., … Hamard, C. (2017). Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature, 545(7654), 360–364.

56.

Papanikolaou, S., Vourda, A., Syggelos, S., & Gyftopoulos, K. (2021). Cell plasticity and prostate cancer: The role of epithelial–mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance. Cancers. https://doi.org/10.3390/cancers13112795CrossRefPubMedPubMedCentral

57.

Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., … Cui, H. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-0110-5

58.

Mavila, N., & Thundimadathil, J. (2019). The emerging roles of cancer stem cells and wnt/beta-catenin signaling in hepatoblastoma. Cancers. https://doi.org/10.3390/cancers11101406CrossRefPubMedPubMedCentral

59.

Ma, S., Lee, T. K., Zheng, B. J., Chan, K. W., & Guan, X. Y. (2008). CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 27(12), 1749. https://doi.org/10.1038/sj.onc.1210811CrossRefPubMed

60.

Kahraman, D. C., Kahraman, T., & Cetin-Atalay, R. (2019). Targeting PI3K/AKT/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment. Molecular Cancer Therapeutics, 18(11), 2146–2157. https://doi.org/10.1158/1535-7163.MCT-19-0004CrossRefPubMed

61.

Wang, R., Sun, Q., Wang, P., Liu, M., Xiong, S., Luo, J., … Cheng, B. (2016). Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget, 7(5), 5754.

62.

Vermeulen, L., De Sousa E Melo, F., Van Der Heijden, M., Cameron, K., De Jong, J. H., Borovski, T., … Medema, J. P. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12(5). https://doi.org/10.1038/ncb2048

63.

Zanconato, F., Battilana, G., Cordenonsi, M., & Piccolo, S. (2016). YAP/TAZ as therapeutic targets in cancer. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2016.05.002CrossRefPubMedPubMedCentral

64.

Nandi, A., Debnath, R., Nayak, A., To, T. K. J., Thacker, G., Reilly, M., … Chakrabarti, R. (2022). Dll1-mediated Notch signaling drives tumor cell cross-talk with cancer-associated fibroblasts to promote radioresistance in breast cancer. Cancer Research, 82(20). https://doi.org/10.1158/0008-5472.CAN-21-1225

65.

Nath, P. R., Pal-Nath, D., Mandal, A., Cam, M. C., Schwartz, A. L., & Roberts, D. D. (2019). Natural killer cell recruitment and activation are regulated by cd47 expression in the tumor microenvironment. Cancer Immunology Research, 7(9), 1547–1561. https://doi.org/10.1158/2326-6066.CIR-18-0367CrossRefPubMedPubMedCentral

66.

Paul, R., Dorsey, J. F., & Fan, Y. (2022). Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications. Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2021.107985CrossRefPubMed

67.

Najafi, M., Mortezaee, K., & Majidpoor, J. (2019). Cancer stem cell (CSC) resistance drivers. Life Sciences. https://doi.org/10.1016/j.lfs.2019.116781CrossRefPubMed

68.

Liu, M., Li, S., & Li, M. O. (2018). TGF-β control of adaptive immune tolerance: A break from Treg cells. BioEssays. https://doi.org/10.1002/bies.201800063CrossRefPubMedPubMedCentral

69.

Shahbaz, S., Bozorgmehr, N., Koleva, P., Namdar, A., Jovel, J., Fava, R. A., & Elahi, S. (2018). CD71 + VISTA + erythroid cells promote the development and function of regulatory T cells through TGF-β. PLoS Biology, 16(12), e2006649. https://doi.org/10.1371/journal.pbio.2006649CrossRefPubMedPubMedCentral

70.

Viel, S., Marçais, A., Guimaraes, F. S. F., Loftus, R., Rabilloud, J., Grau, M., … Walzer, T. (2016). TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Science Signaling, 9(415). https://doi.org/10.1126/scisignal.aad1884

71.

Blanpain, C., & Fuchs, E. (2014). Plasticity of epithelial stem cells in tissue regeneration. Science. https://doi.org/10.1126/science.1242281CrossRefPubMedPubMedCentral

72.

Ha, N. H., Woo, B. H., Kim, D. J., Ha, E. S., Choi, J. Il, Kim, S. J., … Park, H. R. (2015). Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. Tumor Biology, 36, 9947–9960.

73.

Rubinstein, M. R., Wang, X., Liu, W., Hao, Y., Cai, G., & Han, Y. W. (2013). Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host and Microbe, 14(2), 195–206. https://doi.org/10.1016/j.chom.2013.07.012CrossRefPubMed

74.

Wang, Q., Yu, C., Yue, C., & Liu, X. (2020). Fusobacterium nucleatum produces cancer stem cell characteristics via EMT-resembling variations. International Journal of Clinical and Experimental Pathology, 13(7), 1819–1828.PubMedPubMedCentral

75.

Liu, H., Du, J., Chao, S., Li, S., Cai, H., Zhang, H., … Bu, P. (2022). Fusobacterium nucleatum promotes colorectal cancer cell to acquire stem cell-like features by manipulating lipid droplet-mediated numb degradation. Advanced Science, 9(12). https://doi.org/10.1002/advs.202105222

76.

Xia, X., Wu, W. K. K., Wong, S. H., Liu, D., Kwong, T. N. Y., Nakatsu, G., … Yu, J. (2020). Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer. Microbiome, 8(1). https://doi.org/10.1186/s40168-020-00847-4

77.

Szkaradkiewicz, A. K., & Karpiński, T. M. (2013). Microbiology of chronic periodontitis. REVIEW Journal of Biology and Earth Sciences, 3(1), 14–20.

78.

Karpiński, T. M. (2019). Role of oral microbiota in cancer development. Microorganisms, 7(1), 20.CrossRefPubMedPubMedCentral

79.

Inaba, H., Sugita, H., Kuboniwa, M., Iwai, S., Hamada, M., Noda, T., … Amano, A. (2014). Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cellular Microbiology, 16(1). https://doi.org/10.1111/cmi.12211

80.

Yilmaz, Ö., Yao, L., Maeda, K., Rose, T. M., Lewis, E. L., Duman, M., … Ojcius, D. M. (2008). ATP scavenging by the intracellular pathogen Porphyromonas gingivalis inhibits P2X7-mediated host-cell apoptosis. Cellular Microbiology, 10(4). https://doi.org/10.1111/j.1462-5822.2007.01089.x

81.

Yilmaz, Ö., Jungas, T., Verbeke, P., & Ojcius, D. M. (2004). Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. Infection and Immunity, 72(7), 3743–3751. https://doi.org/10.1128/IAI.72.7.3743-3751.2004CrossRefPubMedPubMedCentral

82.

Mao, S., Park, Y., Hasegawa, Y., Tribble, G. D., James, C. E., Handfield, M., … Lamont, R. J. (2007). Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis. Cellular Microbiology, 9(8). https://doi.org/10.1111/j.1462-5822.2007.00931.x

83.

Cai, S., Kandasamy, M., Rahmat, J. N., Tham, S. M., Bay, B. H., Lee, Y. K., & Mahendran, R. (2016). Lactobacillus rhamnosus GG activation of dendritic cells and neutrophils depends on the dose and time of exposure. Journal of Immunology Research, 2016. https://doi.org/10.1155/2016/7402760

84.

Marinelli, L., Tenore, G. C., & Novellino, E. (2017). Probiotic species in the modulation of the anticancer immune response. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2017.08.007CrossRefPubMed

85.

Ye, Z., Petrof, E. O., Boone, D., Claud, E. C., & Sun, J. (2007). Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination. The American journal of pathology, 171(3), 882–892.CrossRefPubMedPubMedCentral

86.

Liu, X., Lu, R., Wu, S., & Sun, J. (2010). Salmonella regulation of intestinal stem cells through the Wnt/β-catenin pathway. FEBS letters, 584(5), 911–916.CrossRefPubMedPubMedCentral

87.

Rogan, M. R., Patterson, L. L., Wang, J. Y., & McBride, J. W. (2019). Bacterial manipulation of wnt signaling: A host-pathogen tug-of-wnt. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02390CrossRefPubMedPubMedCentral

88.

Chung, L., Thiele Orberg, E., Geis, A. L., Chan, J. L., Fu, K., DeStefano Shields, C. E., … Housseau, F. (2018). Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host and Microbe, 23(2). https://doi.org/10.1016/j.chom.2018.01.007

89.

Hwang, S., Lee, C. G., Jo, M., Park, C. O., Gwon, S. Y., Hwang, S., … Rhee, K. J. (2020). Enterotoxigenic bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model. International Journal of Medical Sciences, 17(2). https://doi.org/10.7150/ijms.38371

90.

Lee, Y. S., Kim, T. Y., Kim, Y., Lee, S. H., Kim, S., Kang, S. W., … Kweon, M. N. (2018). Microbiota- derived lactate accelerates intestinal stem-cell-mediated epithelial development. Cell Host and Microbe, 24(6). https://doi.org/10.1016/j.chom.2018.11.002

91.

Banerjee, S., Tian, T., Wei, Z., Shih, N., Feldman, M. D., Peck, K. N., … Robertson, E. S. (2018). Distinct microbial signatures associated with different breast cancer types. Frontiers in Microbiology, 9(MAY). https://doi.org/10.3389/fmicb.2018.00951

92.

Bonnet, M., Buc, E., Sauvanet, P., Darcha, C., Dubois, D., Pereira, B., … Darfeuille-Michaud, A. (2014). Colonization of the human gut by E. coli and colorectal cancer risk. Clinical Cancer Research, 20(4). https://doi.org/10.1158/1078-0432.CCR-13-1343

93.

Sun, J., Robert, M. E., Duan, Y., Rao, A. S., He, T. C., Chang, E. B., & Madara, J. L. (2005). Crosstalk between NF-κB and β-catenin pathways in bacterial-colonized intestinal epithelial cells. American Journal of Physiology - Gastrointestinal and Liver Physiology, 289(1 52–1). https://doi.org/10.1152/ajpgi.00515.2004

94.

Sears, C. L., Geis, A. L., & Housseau, F. (2014). Bacteroides fragilis subverts mucosal biology: From symbiont to colon carcinogenesis. Journal of Clinical Investigation. https://doi.org/10.1172/JCI72334CrossRefPubMedPubMedCentral

95.

Cheng, W. T., Kantilal, H. K., & Davamani, F. (2020). The mechanism of bacteroides fragilis toxin contributes to colon cancer formation. Malaysian Journal of Medical Sciences. https://doi.org/10.21315/mjms2020.27.4.2CrossRef

96.

Wu, S., Rhee, K. J., Zhang, M., Franco, A., & Sears, C. L. (2007). Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage. Journal of Cell Science, 120(11), 1944–1952. https://doi.org/10.1242/jcs.03455CrossRefPubMed

97.

Banerjee, S., Tian, T., Wei, Z., Shih, N., Feldman, M. D., Alwine, J. C., … Robertson, E. S. (2017). The ovarian cancer oncobiome. Oncotarget, 8(22). https://doi.org/10.18632/oncotarget.16717

98.

Zhou, B., Sun, C., Huang, J., Xia, M., Guo, E., Li, N., … Chen, G. (2019). The biodiversity composition of microbiome in ovarian carcinoma patients. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-018-38031-2

99.

Fan, Y., Su, Q., Chen, J., Wang, Y., & He, S. (2022). Gut microbiome alterations affect glioma development and Foxp3 expression in tumor microenvironment in mice. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.836953

100.

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M. L., … Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 359(6371). https://doi.org/10.1126/science.aao3290

101.

Jiang, L., Xiao, X., Ren, J., Tang, Y. Y., Weng, H. Q., Yang, Q., … Tang, W. (2014). Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system. PLoS ONE, 9(6). https://doi.org/10.1371/journal.pone.0098764

102.

Tahara, T., Hirata, I., Nakano, N., Tahara, S., Horiguchi, N., Kawamura, T., … Ohmiya, N. (2017). Potential link between Fusobacterium enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis. Oncotarget, 8(37). https://doi.org/10.18632/oncotarget.18716

103.

Krzysiek-Maczka, G., Targosz, A., Szczyrk, U., Strzałka, M., Sliwowski, Z., Brzozowski, T., … Ptak-Belowska, A. (2018). Role of Helicobacter pylori infection in cancer-associated fibroblast-induced epithelial-mesenchymal transition in vitro. Helicobacter, 23(6). https://doi.org/10.1111/hel.12538

104.

Bessède, E., Staedel, C., Acuña Amador, L. A., Nguyen, P. H., Chambonnier, L., Hatakeyama, M., … Varon, C. (2014). Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene, 33(32). https://doi.org/10.1038/onc.2013.380

105.

Sohn, S.-H., Kim, N., Jo, H. J., Kim, J., Park, J. H., Nam, R. H., … Lee, D. H. (2017). Analysis of gastric body microbiota by pyrosequencing: Possible role of bacteria other than Helicobacter pylori in the gastric carcinogenesis. Journal of cancer prevention, 22(2), 115.

106.

Łaniewski, P., Barnes, D., Goulder, A., Cui, H., Roe, D. J., Chase, D. M., & Herbst-Kralovetz, M. M. (2018). Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-25879-7

107.

Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., … Garrett, W. S. (2013). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host and Microbe, 14(2). https://doi.org/10.1016/j.chom.2013.07.007

108.

Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., … Jacks, T. (2019). Commensal microbiota promote lung cancer development via γδ T cells. Cell, 176(5). https://doi.org/10.1016/j.cell.2018.12.040

109.

Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., … Bullman, S. (2022). Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature, 611(7937). https://doi.org/10.1038/s41586-022-05435-0

110.

Kaiko, G. E., Ryu, S. H., Koues, O. I., Collins, P. L., Solnica-Krezel, L., Pearce, E. J., … Stappenbeck, T. S. (2016). The colonic crypt protects stem cells from microbiota-derived metabolites. Cell, 165(7). https://doi.org/10.1016/j.cell.2016.05.018

111.

Lozenov, S., Krastev, B., Nikolaev, G., Peshevska-Sekulovska, M., Peruhova, M., & Velikova, T. (2023). Gut microbiome composition and its metabolites are a key regulating factor for malignant transformation, metastasis and antitumor immunity. International Journal of Molecular Sciences, 24(6), 5978.CrossRefPubMedPubMedCentral

112.

Yu, T. C., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., … Fang, J. Y. (2017). Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell, 170(3). https://doi.org/10.1016/j.cell.2017.07.008

113.

Yan, X., Liu, L., Li, H., Qin, H., & Sun, Z. (2017). Clinical significance of Fusobacterium nucleatum, epithelial–mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. OncoTargets and therapy, pp. 5031–5046.

114.

Gao, Y., Bi, D., Xie, R., Li, M., Guo, J., Liu, H., … Qin, H. (2021). Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduction and Targeted Therapy, 6(1). https://doi.org/10.1038/s41392-021-00795-x

115.

Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., … Roberti, M. P. (2021). Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. Cell Death and Differentiation, 28(5). https://doi.org/10.1038/s41418-020-00684-w

116.

Zheng, D. W., Dong, X., Pan, P., Chen, K. W., Fan, J. X., Cheng, S. X., & Zhang, X. Z. (2019). Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nature Biomedical Engineering, 3(9), 717–728. https://doi.org/10.1038/s41551-019-0423-2CrossRefPubMed

117.

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., … Zitvogel, L. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 359(6371). https://doi.org/10.1126/science.aan3706

118.

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., … Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350(6264). https://doi.org/10.1126/science.aac4255

119.

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., … Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 342(6161). https://doi.org/10.1126/science.1240537

120.

Gui, Q. F., Lu, H. F., Zhang, C. X., Xu, Z. R., & Yang, Y. M. (2015). Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genetics and Molecular Research, 14(2), 5642–5651. https://doi.org/10.4238/2015.May.25.16CrossRefPubMed

121.

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., … Carbonnel, F. (2017). Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of Oncology, 28(6). https://doi.org/10.1093/annonc/mdx108

122.

Si, W., Liang, H., Bugno, J., Xu, Q., Ding, X., Yang, K., … Wang, L. (2022). Lactobacillus rhamnosus GG induces cGAS/STING- dependent type i interferon and improves response to immune checkpoint blockade. Gut, 71(3). https://doi.org/10.1136/gutjnl-2020-323426

123.

Österlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., … Joensuu, H. (2007). Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. British Journal of Cancer, 97(8). https://doi.org/10.1038/sj.bjc.6603990

124.

Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., … McCoy, K. D. (2020). Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science, 369(6509). https://doi.org/10.1126/SCIENCE.ABC3421

125.

Smith, C. L., Geier, M. S., Yazbeck, R., Torres, D. M., Butler, R. N., & Howarth, G. S. (2008). Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutrition and Cancer, 60(6), 757–767. https://doi.org/10.1080/01635580802192841CrossRefPubMed

126.

Quaresma, M., Damasceno, S., Monteiro, C., Lima, F., Mendes, T., Lima, M., … Soares, P. (2020). Probiotic mixture containing Lactobacillus spp. and Bifidobacterium spp. attenuates 5-fluorouracil-induced intestinal mucositis in mice. Nutrition and Cancer, 72(8). https://doi.org/10.1080/01635581.2019.1675719

127.

Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S. J., Hannam, S., & Keefe, D. M. K. (2007). VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biology and Therapy, 6(9), 1445–1450. https://doi.org/10.4161/cbt.6.9.4622CrossRef

128.

Mi, H., Dong, Y., Zhang, B., Wang, H., Peter, C. C. K., Gao, P., … Gao, Y. (2017). Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats. Cellular Physiology and Biochemi. Cellular Physiology and Biochemistry, 42(6). https://doi.org/10.1159/000480005

129.

Motoori, M., Yano, M., Miyata, H., Sugimura, K., Saito, T., Omori, T., … Sakon, M. (2017). Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clinical Nutrition, 36(1). https://doi.org/10.1016/j.clnu.2015.11.008

130.

Porto, B. A. A., Monteiro, C. F., Souza, É. L. S., Leocádio, P. C. L., Alvarez-Leite, J. I., Generoso, S. V., … Martins, F. S. (2019). Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice. Cancer Chemotherapy and Pharmacology, 84(1). https://doi.org/10.1007/s00280-019-03865-8

131.

Justino, P. F. C., Melo, L. F. M., Nogueira, A. F., Morais, C. M., Mendes, W. O., Franco, A. X., … Soares, P. M. G. (2015). Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice. Cancer Chemotherapy and Pharmacology, 75(3). https://doi.org/10.1007/s00280-014-2663-x

132.

Tang, Y., Wu, Y., Huang, Z., Dong, W., Deng, Y., Wang, F., … Yuan, J. (2017). Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil–induced intestinal mucositis and dysbiosis in rats. Nutrition, 33. https://doi.org/10.1016/j.nut.2016.05.003

133.

Kim, S. I., Park, A. K., Chaurasiya, S., Kang, S., Lu, J., Yang, A., … Warner, S. G. (2021). Recombinant orthopoxvirus primes colon cancer for checkpoint inhibitor and cross-primes T cells for antitumor and antiviral immunity. Molecular Cancer Therapeutics, 20(1). https://doi.org/10.1158/1535-7163.MCT-20-0405

134.

Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., … Honda, K. (2019). A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature, 565(7741). https://doi.org/10.1038/s41586-019-0878-z

135.

Ma, J., Huang, L., Hu, D., Zeng, S., Han, Y., & Shen, H. (2021). The role of the tumor microbe microenvironment in the tumor immune microenvironment: Bystander, activator, or inhibitor? Journal of Experimental and Clinical Cancer Research. https://doi.org/10.1186/s13046-021-02128-wCrossRefPubMedPubMedCentral

136.

Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., … Fu, Y. X. (2020). Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. Journal of Experimental Medicine, 217(5). https://doi.org/10.1084/jem.20192282

137.

Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020). Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.02989CrossRefPubMedPubMedCentral

138.

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., … Zitvogel, L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264). https://doi.org/10.1126/science.aad1329

139.

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., … Zitvogel, L. (2020). Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage. Science, 369(6506). https://doi.org/10.1126/science.aax0701

140.

Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., … Miller, G. (2018). The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discovery, 8(4). https://doi.org/10.1158/2159-8290.CD-17-1134

141.

Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., … Zitvogel, L. (2016). Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity, 45(4). https://doi.org/10.1016/j.immuni.2016.09.009

142.

Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023). Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology. https://doi.org/10.1053/j.gastro.2022.10.018CrossRefPubMed

143.

Lin, X. B., Dieleman, L. A., Ketabi, A., Bibova, I., Sawyer, M. B., Xue, H., … Gänzle, M. G. (2012). Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS ONE, 7(7). https://doi.org/10.1371/journal.pone.0039764

144.

Jia, Y., & Xie, J. (2015). Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes and Diseases. https://doi.org/10.1016/j.gendis.2015.07.003CrossRefPubMedPubMedCentral

145.

Bhatt, A. P., Pellock, S. J., Biernat, K. A., Walton, W. G., Wallace, B. D., Creekmore, B. C., … Redinbo, M. R. (2020). Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proceedings of the National Academy of Sciences of the United States of America, 117(13). https://doi.org/10.1073/pnas.1918095117

146.

Pollet, R. M., D’Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., … Redinbo, M. R. (2017). An atlas of β-glucuronidases in the human intestinal microbiome. Structure, 25(7). https://doi.org/10.1016/j.str.2017.05.003

147.

Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., … Redinbo, M. R. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 330(6005). https://doi.org/10.1126/science.1191175

148.

Kodawara, T., Higashi, T., Negoro, Y., Kamitani, Y., Igarashi, T., Watanabe, K., … Iwasaki, H. (2016). The inhibitory effect of ciprofloxacin on the β‐glucuronidase‐mediated deconjugation of the irinotecan metabolite SN‐38‐G. Basic & clinical pharmacology & toxicology, 118(5), 333–337.

149.

Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., … Straussman, R. (2017). Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 357(6356). https://doi.org/10.1126/science.aah5043

150.

Voorde, J. Vande, Sabuncuoǧlu, S., Noppen, S., Hofer, A., Ranjbarian, F., Fieuws, S., … Liekens, S. (2014). Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. Journal of Biological Chemistry, 289(19). https://doi.org/10.1074/jbc.M114.558924

151.

Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., … Tangney, M. (2015). Local bacteria affect the efficacy of chemotherapeutic drugs. Scientific Reports, 5. https://doi.org/10.1038/srep14554

152.

Scott, T. A., Quintaneiro, L. M., Norvaisas, P., Lui, P. P., Wilson, M. P., Leung, K. Y., … Cabreiro, F. (2017). Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell, 169(3). https://doi.org/10.1016/j.cell.2017.03.040

153.

Michaud, D. S., Izard, J., Wilhelm-Benartzi, C. S., You, D. H., Grote, V. A., Tjønneland, A., … Riboli, E. (2013). Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut, 62(12). https://doi.org/10.1136/gutjnl-2012-303006

154.

Korecka, A., De Wouters, T., Cultrone, A., Lapaque, N., Pettersson, S., Doré, J., … Arulampalam, V. (2013). ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways. American Journal of Physiology-Gastrointestinal and Liver Physiology, 304(11), G1025–G1037.

155.

Jones, R. M., Desai, C., Darby, T. M., Luo, L., Wolfarth, A. A., Scharer, C. D., … Neish, A. S. (2015). Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. Cell Reports, 12(8). https://doi.org/10.1016/j.celrep.2015.07.042

156.

Ciorba, M. A., Riehl, T. E., Rao, M. S., Moon, C., Ee, X., Nava, G. M., … Stenson, W. F. (2012). Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut, 61(6). https://doi.org/10.1136/gutjnl-2011-300367

157.

Jones, R. M., Luo, L., Ardita, C. S., Richardson, A. N., Kwon, Y. M., Mercante, J. W., … Neish, A. S. (2013). Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. EMBO Journal, 32(23). https://doi.org/10.1038/emboj.2013.224

158.

Blanarova, C., Galovicova, A., & Petrasova, D. (2009). Use of probiotics for prevention of radiation-induced diarrhea. Bratislava Medical Journal, 110(2), 98–104.PubMed

159.

Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley Des Varannes, S., … De La Cochetière, M. F. (2014). Systematic review: The role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - Current evidence and potential clinical applications. Alimentary Pharmacology and Therapeuticshttps://doi.org/10.1111/apt.12878

160.

Sharma, A., Rath, G. K., Chaudhary, S. P., Thakar, A., Mohanti, B. K., & Bahadur, S. (2012). Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study. European Journal of Cancer, 48(6), 875–881. https://doi.org/10.1016/j.ejca.2011.06.010CrossRefPubMed

161.

Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., … McAllister, F. (2019). Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell, 178(4). https://doi.org/10.1016/j.cell.2019.07.008

162.

Jeffery, I. B., & O’Toole, P. W. (2013). Diet-microbiota interactions and their implications for healthy living. Nutrients. https://doi.org/10.3390/nu5010234CrossRefPubMedPubMedCentral

163.

Paul, B., Barnes, S., Demark-Wahnefried, W., Morrow, C., Salvador, C., Skibola, C., & Tollefsbol, T. O. (2015). Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clinical Epigenetics. https://doi.org/10.1186/s13148-015-0144-7CrossRefPubMedPubMedCentral

164.

Chiba, A., Bawaneh, A., Velazquez, C., Clear, K. Y. J., Wilson, A. S., Howard-McNatt, M., … Cook, K. L. (2020). Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Molecular Cancer Research, 18(1). https://doi.org/10.1158/1541-7786.MCR-19-0451

165.

Stojanovska, V., McQuade, R. M., Fraser, S., Prakash, M., Gondalia, S., Stavely, R., … Nurgali, K. (2018). Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS ONE, 13(6). https://doi.org/10.1371/journal.pone.0198359

166.

Chiang, N. J., Tsai, K. K., Hsiao, C. F., Yang, S. H., Hsiao, H. H., Shen, W. C., … Chen, L. T. (2020). A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study. European Journal of Cancer, 124. https://doi.org/10.1016/j.ejca.2019.10.023

167.

Ternes, D., Tsenkova, M., Pozdeev, V. I., Meyers, M., Koncina, E., Atatri, S., … Letellier, E. (2022). The gut microbial metabolite formate exacerbates colorectal cancer progression. Nature Metabolism, 4(4). https://doi.org/10.1038/s42255-022-00558-0

168.

He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., … Guo, X. (2021). Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metabolism, 33(5). https://doi.org/10.1016/j.cmet.2021.03.002

169.

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., … Pal, S. K. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 28(4). https://doi.org/10.1038/s41591-022-01694-6

170.

Chen, Y., Wu, F. H., Wu, P. Q., Xing, H. Y., & Ma, T. (2022). The role of the tumor microbiome in tumor development and its treatment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.935846CrossRefPubMedPubMedCentral

171.

Geier, M. S., Butler, R. N., & Howarth, G. S. (2006). Probiotics, prebiotics and synbiotics: A role in chemoprevention for colorectal cancer? Cancer Biology and Therapy. https://doi.org/10.4161/cbt.5.10.3296CrossRefPubMed

Titel: The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance
verfasst von: Priya Mondal
Syed Musthapa Meeran
Publikationsdatum: 14.09.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10138-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Clusterin: a marker and mediator of chemoresistance in colorectal cancer

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Resveratrol as sensitizer in colorectal cancer plasticity

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie